Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merck

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

45 comunicati stampa

Guarda tutti i comunicati
29/10/2026
Annunci Economici
Merck Opens €300 Million Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea
Fonte
Merck
Emittente
GLOBENEWSWIRE
1.00
0
26/10/2026
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
Fonte
Merck
Emittente
Business Wire
1.00
0
21/10/2026
Sanità
Software
Information Technology
Tecnica
Medicina - Varie
Biotecnologia
Tecnologie Varie
Salute
Mercato del lavoro
Industria
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
Fonte
Merck
Emittente
Business Wire
1.00
0
16/07/2026
Annunci Economici
Merck Opens BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
Fonte
Merck
Emittente
GLOBENEWSWIRE
1.00
0
14/07/2026
Scienza
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Oncologia
Industria
European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation
Fonte
Merck
Emittente
Business Wire
1.00
0
08/07/2026
Sanità
Scienza
Farmaceutica
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
Industria
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations
Fonte
Merck
Emittente
Business Wire
1.00
0
23/06/2026
Mercato del lavoro
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
Fonte
Merck
Emittente
Business Wire
1.00
0
08/06/2026
Annunci Economici
Merck Appoints New Heads of Discovery Solutions and Strategy & Business Development for Life Science Business Sector
Fonte
Merck
Emittente
GLOBENEWSWIRE
1.00
0
21/05/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Industria
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Fonte
Merck
Emittente
Business Wire
1.00
0
07/05/2026
Annunci Economici
Merck Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
Fonte
Merck
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0